Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
11 slides from Hikma Pharmaceuticals's conference presentation, January 2025
Slide 1: Better health. Within reach. Every day.
Better health. Within reach. Every day. Hikma Pharmaceuticals PLC J.P. Morgan Healthcare Conference January 2025
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Strategic overview
Strategic overview Riad Mishlawi, Chief Executive Officer
Slide 4: Our track record of growth and healthy cash generation
Our track record of growth and healthy cash generation Core revenue Core EBITDA Operating cash flow (millions) (millions) (millions) +7% CAGR +8% CAGR $638 $811 $608 $2,875 $727 $530 $674 $695 $2,553 $2,517 $472 $464 $2,341 $593 $2,203 27% 29% 28% 28% 28% 2019 2020 2021 2022 2023 2019 2020 2021 2022
Slide 5: Executing on four pillars of value creation
Executing on four pillars of value creation Increasingly A solid platform diverse portfolio with a unique and pipeline business model A proven track Strong financial position record and a clear underpins growth ambition strategy for growth Hikma Pharmaceuticals PLC 5
Slide 6: A solid platform with a unique business model
Executing on four pillars of value creation A solid platform with a unique business model Leading Large and Expansive market positions growing portfolio manufacturing footprint 7th largest in the US1 +760 products 29 plants 2nd largest in MENA2 • Expanded market reach in Europe • Launched 59 product
Slide 7: A solid platform with a unique business model
Executing on four pillars of value creation A solid platform with a unique business model Adding to the strength of our base business through the Xellia acquisition 8 approved and marketed products and Cleveland site offers end-to-end manufacturing 11 pipeline products capabilities and adds complex
Slide 8: Increasingly diverse portfolio and pipeline
Executing on four pillars of value creation Increasingly diverse portfolio and pipeline >300 6%-7% Across the Group we are looking at: Increasing the complexity of Improving the quality of our Utilising our internal API products target spend of our pipeline through filings for higher rate of first c
Slide 9: A proven track record and clear strategy for growth
Executing on four pillars of value creation A proven track record and clear strategy for growth Consistently delivering Our clear path to continue delivering Strong strong growth consistent and profitable growth 2024 guidance 5-year Revenue revenue CAGR growth: +7% 6% CAGR to 8% 5-year Core core EBI
Slide 10: Strong financial position underpins growth ambition
Executing on four pillars of value creation Strong financial position underpins growth ambition Consistently delivering industry-leading Strong balance sheet and a high EBITDA margins and strong cash generation return on capital $811 $674 $727 $695 Net debt/core EBITDA 1.3x1 $593 27% 29% 29% 28% 28%
Slide 11: Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC 11
Hikma Pharmaceuticals — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix